GLP-1 Peripregnancy, Normal Tissue Characterization, and CVD Risk Assessment

TT HealthWatch
28/11/2025 11 min

Listen "GLP-1 Peripregnancy, Normal Tissue Characterization, and CVD Risk Assessment"

Descargar episodio Ver en sitio original

Episode Synopsis

Program notes:0:40 CVD risk factors and texting1:40 How many undergo screening?2:41 Impact of personalized messaging3:25 Decentralized trials versus centralized 4:25 Decentralized much larger5:25 Does the trial move in one way or another?6:15 Two studies related to use of peripregnancy GLP-1 use7:15 Stopping at pregnancy8:15 Is overweight worse than stopping?9:00 Machine learning model, tissues, genetics and age10:00 Practical for assessing genetic basis11:00 Sequential tissue samples11:57 End

More episodes of the podcast TT HealthWatch

Acetaminophen, clinical trials, supplementing potassium, mRNA flu vaccines 21/11/2025
Meds after afib ablation, fish oil, therapy for stents 14/11/2025
Oral med for obesity, stem cells after heart failure, blood markers and MS, and predicting atherosclerosis 07/11/2025
AI and diabetes, knee OA exercises, Mediterranean diet, IBS, and steps for health 31/10/2025
Nicotine, Heart Surgery, Maternal PFAS exposure and Blood Pressure 24/10/2025
Social media and adolescents, gene therapy for ADA deficiency, SLE treatment, AI in health care 17/10/2025
Obesity medicines, aldosterone and CVD, inhalers, and antibiotic importation 10/10/2025
RSV, Cancer Risk, Pulmonary Hypertension, Bronchiectasis 03/10/2025
Dementia, Type 1 Diabetes, and Private Equity 26/09/2025
Breast cancer, stalking and CVD, dementia, and lipoprotein(a) 19/09/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA